Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Not Tempted To Join COVID-19 Vaccines Race

No Longer Has Capabilities After GSK Asset Swap

Jul 21 2020

• By Kevin Grogan

Doctor, nurse, scientist hand in blue gloves holding flu, measles, coronavirus, covid-19 vaccine disease preparing for child, baby, adult, man and woman vaccination shot, medicine and drug concept. — Novartis not returning to vaccine development • Source: Shutterstock

Related Content

Swapping Assets Now Down To Execution For GSK And Novartis

Mar 02 2015

Novartis Unveils Zero Profit COVID-19 Drugs Portfolio

Jul 16 2020

Solid Phase I Results For AstraZeneca COVID-19 Vaccine, But Two Doses Needed To Hit Efficacy Goal

Jul 20 2020

New Pfizer/BioNTech COVID-19 Vaccine Data Confirm Prior Results, Show T-Cell Boost

Jul 21 2020

CanSino Confirms Immune Response For Coronavirus Vaccine But Safety Concerns Remain

Jul 21 2020

Related Companies

Novartis AG

GSK plc

Incyte Corporation

Pfizer Inc.

BioNTech SE

AstraZeneca PLC

CanSino Biologics Inc.

Additional Topics

Vaccines Coronavirus COVID-19 Strategy Clinical Trials Companies Research & Development Leadership BioPharmaceutical

More from COVID-19

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window